[{"id":"e403d404-bc05-4817-9ff3-f97c2077e32b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03449381","created_at":"2021-01-18T17:00:34.045Z","updated_at":"2025-02-25T14:15:08.572Z","phase":"Phase 1","brief_title":"This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)","source_id_and_acronym":"NCT03449381","lead_sponsor":"Boehringer Ingelheim","biomarkers":" TP53 • MDM2","pipe":" | ","alterations":" TP53 wild-type","tags":["TP53 • MDM2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e brigimadlin (BI 907828)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 267","initiation":"Initiation: 06/20/2018","start_date":" 06/20/2018","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-18"},{"id":"c9d1a579-ede0-4060-a970-738063622323","acronym":"","url":"https://clinicaltrials.gov/study/NCT03654716","created_at":"2021-01-18T17:56:08.387Z","updated_at":"2025-02-25T14:40:01.342Z","phase":"Phase 1","brief_title":"Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer","source_id_and_acronym":"NCT03654716","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" TP53 • MDM2 • TET2 • SMARCB1 • PPM1D","pipe":" | ","alterations":" TP53 wild-type • TET2 mutation","tags":["TP53 • MDM2 • TET2 • SMARCB1 • PPM1D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type • TET2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • sulanemadlin (ALRN-6924)"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 11/01/2018","start_date":" 11/01/2018","primary_txt":" Primary completion: 07/17/2023","primary_completion_date":" 07/17/2023","study_txt":" Completion: 07/17/2023","study_completion_date":" 07/17/2023","last_update_posted":"2025-02-14"},{"id":"9518cf2f-a488-48b8-a437-c584bd916e0c","acronym":"Brightline-2","url":"https://clinicaltrials.gov/study/NCT05512377","created_at":"2022-08-23T14:55:35.585Z","updated_at":"2025-02-25T15:19:58.742Z","phase":"Phase 2","brief_title":"Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder","source_id_and_acronym":"NCT05512377 - Brightline-2","lead_sponsor":"Boehringer Ingelheim","biomarkers":" TP53 • MDM2","pipe":" | ","alterations":" TP53 wild-type","tags":["TP53 • MDM2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e brigimadlin (BI 907828)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 99","initiation":"Initiation: 12/13/2022","start_date":" 12/13/2022","primary_txt":" Primary completion: 06/10/2025","primary_completion_date":" 06/10/2025","study_txt":" Completion: 06/10/2025","study_completion_date":" 06/10/2025","last_update_posted":"2025-02-11"},{"id":"48bd9dcf-d292-48b2-a409-af70759d67b7","acronym":"Brightline-4","url":"https://clinicaltrials.gov/study/NCT06058793","created_at":"2023-09-28T14:10:28.336Z","updated_at":"2025-02-25T15:20:51.763Z","phase":"Phase 3","brief_title":"Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma","source_id_and_acronym":"NCT06058793 - Brightline-4","lead_sponsor":"Boehringer Ingelheim","biomarkers":" MDM2","pipe":" | ","alterations":" MDM2 amplification","tags":["MDM2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MDM2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e brigimadlin (BI 907828)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 138","initiation":"Initiation: 12/13/2023","start_date":" 12/13/2023","primary_txt":" Primary completion: 07/07/2025","primary_completion_date":" 07/07/2025","study_txt":" Completion: 07/07/2025","study_completion_date":" 07/07/2025","last_update_posted":"2025-02-10"},{"id":"4b0f1350-ce19-4057-8fd9-f2b662d41e4f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06025747","created_at":"2023-09-06T14:09:40.441Z","updated_at":"2025-02-25T16:55:17.296Z","phase":"Phase 1","brief_title":"Evaluation of Abemaciclib and Radiation Therapy Before Surgery for the Treatment of High-Risk Adipocytic Retroperitoneal Sarcoma","source_id_and_acronym":"NCT06025747","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" MDM2 • CDK4","pipe":" | ","alterations":" CDK4 amplification","tags":["MDM2 • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDK4 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 02/09/2025","start_date":" 02/09/2025","primary_txt":" Primary completion: 03/03/2025","primary_completion_date":" 03/03/2025","study_txt":" Completion: 03/03/2026","study_completion_date":" 03/03/2026","last_update_posted":"2025-02-04"},{"id":"ed857d81-c1db-430d-8754-fe70af84d781","acronym":"STRASS 2","url":"https://clinicaltrials.gov/study/NCT04031677","created_at":"2021-01-18T19:47:11.156Z","updated_at":"2025-02-25T17:24:14.778Z","phase":"Phase 3","brief_title":"Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma","source_id_and_acronym":"NCT04031677 - STRASS 2","lead_sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","biomarkers":" MDM2 • CDK4","pipe":" | ","alterations":" MDM2 amplification","tags":["MDM2 • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MDM2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • epirubicin"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 01/20/2021","start_date":" 01/20/2021","primary_txt":" Primary completion: 04/21/2027","primary_completion_date":" 04/21/2027","study_txt":" Completion: 04/21/2028","study_completion_date":" 04/21/2028","last_update_posted":"2025-01-31"},{"id":"69e83241-ea93-4a7c-a2c5-2fc40b9cacd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03964233","created_at":"2021-01-18T19:30:14.916Z","updated_at":"2024-07-02T16:34:27.457Z","phase":"Phase 1","brief_title":"A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)","source_id_and_acronym":"NCT03964233","lead_sponsor":"Boehringer Ingelheim","biomarkers":" TP53 • MDM2","pipe":" | ","alterations":" TP53 mutation • TP53 wild-type • TP53 amplification","tags":["TP53 • MDM2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 wild-type • TP53 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e brigimadlin (BI 907828) • ezabenlimab (BI 754091) • miptenalimab (BI 754111)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 119","initiation":"Initiation: 06/11/2019","start_date":" 06/11/2019","primary_txt":" Primary completion: 09/03/2024","primary_completion_date":" 09/03/2024","study_txt":" Completion: 05/30/2026","study_completion_date":" 05/30/2026","last_update_posted":"2024-06-11"},{"id":"1532ca3a-2502-4dd2-b1ac-69ae84a9d9a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04785196","created_at":"2021-03-05T12:55:16.352Z","updated_at":"2024-07-02T16:34:37.707Z","phase":"Phase 1/2","brief_title":"APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors","source_id_and_acronym":"NCT04785196","lead_sponsor":"Ascentage Pharma Group Inc.","biomarkers":" TP53 • MDM2","pipe":" | ","alterations":" MDM2 amplification","tags":["TP53 • MDM2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MDM2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • alrizomadlin (APG-115)"],"overall_status":"Recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 05/26/2021","start_date":" 05/26/2021","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-06-06"},{"id":"4495832a-2153-4225-9985-32a8ffb570e3","acronym":"","url":"https://clinicaltrials.gov/study/NCT06436846","created_at":"2024-05-31T20:35:33.470Z","updated_at":"2024-07-02T16:34:59.819Z","phase":"","brief_title":"Genomic Risk in Retroperitoneal Sarcoma","source_id_and_acronym":"NCT06436846","lead_sponsor":"Fox Chase Cancer Center","biomarkers":" MDM2","pipe":"","alterations":" ","tags":["MDM2"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 03/07/2022","start_date":" 03/07/2022","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2024-05-31"},{"id":"8945fb8d-c675-4151-861b-f34bbc81d66c","acronym":"Brightline-1","url":"https://clinicaltrials.gov/study/NCT05218499","created_at":"2022-02-05T18:28:26.477Z","updated_at":"2024-07-02T16:35:02.156Z","phase":"Phase 2/3","brief_title":"Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma","source_id_and_acronym":"NCT05218499 - Brightline-1","lead_sponsor":"Boehringer Ingelheim","biomarkers":" MDM2","pipe":" | ","alterations":" MDM2 amplification","tags":["MDM2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MDM2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • brigimadlin (BI 907828)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 03/25/2022","start_date":" 03/25/2022","primary_txt":" Primary completion: 04/16/2024","primary_completion_date":" 04/16/2024","study_txt":" Completion: 05/27/2026","study_completion_date":" 05/27/2026","last_update_posted":"2024-05-22"},{"id":"c26f7e4c-301c-4f7a-9c9b-fcbebe86dda6","acronym":"NRG-DT001","url":"https://clinicaltrials.gov/study/NCT03217266","created_at":"2021-01-18T15:52:30.675Z","updated_at":"2024-07-02T16:35:02.993Z","phase":"Phase 1","brief_title":"Navtemadlin and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma","source_id_and_acronym":"NCT03217266 - NRG-DT001","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • MDM2 • MDM4 • CD4","pipe":"","alterations":" ","tags":["TP53 • MDM2 • MDM4 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e navtemadlin (KRT-232)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 06/20/2018","start_date":" 06/20/2018","primary_txt":" Primary completion: 08/27/2023","primary_completion_date":" 08/27/2023","study_txt":" Completion: 02/28/2025","study_completion_date":" 02/28/2025","last_update_posted":"2024-05-17"},{"id":"95af92d3-7ef1-42bc-8075-503c2a4324fc","acronym":"","url":"https://clinicaltrials.gov/study/NCT03975387","created_at":"2021-01-18T19:33:08.305Z","updated_at":"2024-07-02T16:35:05.855Z","phase":"Phase 1/2","brief_title":"Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53","source_id_and_acronym":"NCT03975387","lead_sponsor":"Astex Pharmaceuticals, Inc.","biomarkers":" TP53 • MDM2","pipe":" | ","alterations":" TP53 wild-type • MDM2 amplification","tags":["TP53 • MDM2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type • MDM2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ASTX295"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 07/11/2019","start_date":" 07/11/2019","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-05-06"},{"id":"8626d796-d31d-4f11-a4ab-8ea3dce4cf77","acronym":"","url":"https://clinicaltrials.gov/study/NCT03725436","created_at":"2021-01-18T18:15:21.875Z","updated_at":"2024-07-02T16:35:08.781Z","phase":"Phase 1","brief_title":"ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors","source_id_and_acronym":"NCT03725436","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • ER • TP53 • MDM2 • MDM4 • GDF15 • CASP3 • CDKN1A","pipe":" | ","alterations":" ER positive • HER-2 negative • TP53 wild-type • MDM4 amplification • MDM2 mutation • TP53 amplification","tags":["HER-2 • ER • TP53 • MDM2 • MDM4 • GDF15 • CASP3 • CDKN1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • TP53 wild-type • MDM4 amplification • MDM2 mutation • TP53 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • sulanemadlin (ALRN-6924)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 01/24/2019","start_date":" 01/24/2019","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2024-04-18"},{"id":"23fbfd55-0bea-4321-83e6-d320991b3c5c","acronym":"AMPHISARC","url":"https://clinicaltrials.gov/study/NCT05180695","created_at":"2022-01-06T22:53:30.960Z","updated_at":"2025-02-25T15:54:18.762Z","phase":"Phase 1/2","brief_title":"HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas","source_id_and_acronym":"NCT05180695 - AMPHISARC","lead_sponsor":"Centre Leon Berard","biomarkers":" MDM2","pipe":" | ","alterations":" TP53 wild-type","tags":["MDM2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pazopanib • siremadlin (HDM201)"],"overall_status":"Recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 04/15/2022","start_date":" 04/15/2022","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2024-04-08"},{"id":"feb3ead4-c6a6-457d-b33b-1a2946c2b846","acronym":"NATARS","url":"https://clinicaltrials.gov/study/NCT05844813","created_at":"2023-05-06T15:04:30.757Z","updated_at":"2024-07-02T16:35:48.112Z","phase":"Phase 4","brief_title":"Neoadjuvant Chemotherapy Combined With Targeted Treatment in High-risk Retroperitoneal Sarcoma","source_id_and_acronym":"NCT05844813 - NATARS","lead_sponsor":"Peking University International Hospital","biomarkers":" MDM2 • CDK4","pipe":" | ","alterations":" MDM2 amplification","tags":["MDM2 • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MDM2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • doxorubicin hydrochloride • ifosfamide"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 102","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2023-05-12"},{"id":"7cfa6f26-875f-4193-9aef-c545fb2ab82d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03554707","created_at":"2021-01-18T17:29:50.207Z","updated_at":"2024-07-02T16:36:17.444Z","phase":"Phase 1","brief_title":"SGT-53 in Children With Recurrent or Progressive CNS Malignancies","source_id_and_acronym":"NCT03554707","lead_sponsor":"SynerGene Therapeutics, Inc.","biomarkers":" MGMT • MDM2 • CDKN1A","pipe":" | ","alterations":" ATRX mutation • MDM2 mutation","tags":["MGMT • MDM2 • CDKN1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATRX mutation • MDM2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • temozolomide • irinotecan • Onivyde (nanoliposomal irinotecan) • SGT-53"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 06/01/2022","start_date":" 06/01/2022","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2022-02-08"},{"id":"613e409a-9659-4396-bba3-22b9a39d0fcd","acronym":"","url":"https://clinicaltrials.gov/study/NCT01877382","created_at":"2021-01-18T08:26:57.296Z","updated_at":"2024-07-02T16:36:37.709Z","phase":"Phase 1","brief_title":"A Phase 1 Multiple Ascending Dose Study of Milademetan in Subjects With Advanced Solid Tumors or Lymphomas","source_id_and_acronym":"NCT01877382","lead_sponsor":"Daiichi Sankyo, Inc.","biomarkers":" TP53 • MDM2 • GDF15","pipe":" | ","alterations":" TP53 mutation • MDM2 amplification • MDM2 overexpression","tags":["TP53 • MDM2 • GDF15"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • MDM2 amplification • MDM2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e milademetan (RAIN-32)"],"overall_status":"Completed","enrollment":" Enrollment 108","initiation":"Initiation: 07/01/2013","start_date":" 07/01/2013","primary_txt":" Primary completion: 10/08/2020","primary_completion_date":" 10/08/2020","study_txt":" Completion: 12/03/2020","study_completion_date":" 12/03/2020","last_update_posted":"2020-12-08"},{"id":"e4814374-bf8c-49be-a21a-62807e022dee","acronym":"FILIPO","url":"https://clinicaltrials.gov/study/NCT03303885","created_at":"2021-01-18T16:19:10.361Z","updated_at":"2024-07-02T16:36:39.957Z","phase":"","brief_title":"The FGF/FGFR Signalling Pathway:","source_id_and_acronym":"NCT03303885 - FILIPO","lead_sponsor":"Centre Hospitalier Universitaire de Nice","biomarkers":" MDM2 • FGF18","pipe":"","alterations":" ","tags":["MDM2 • FGF18"],"overall_status":"Completed","enrollment":" Enrollment 421","initiation":"Initiation: 10/01/2017","start_date":" 10/01/2017","primary_txt":" Primary completion: 03/29/2019","primary_completion_date":" 03/29/2019","study_txt":" Completion: 03/29/2019","study_completion_date":" 03/29/2019","last_update_posted":"2020-10-19"},{"id":"592b7eaa-b0b9-44ec-a9e0-7a40a914198a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02264613","created_at":"2021-01-18T10:39:31.889Z","updated_at":"2024-07-02T16:36:43.300Z","phase":"Phase 1/2","brief_title":"ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas","source_id_and_acronym":"NCT02264613","lead_sponsor":"Aileron Therapeutics, Inc.","biomarkers":" TP53 • MDM2 • CDK4","pipe":" | ","alterations":" TP53 wild-type • MDM2 amplification • CDK4 amplification","tags":["TP53 • MDM2 • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type • MDM2 amplification • CDK4 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sulanemadlin (ALRN-6924)"],"overall_status":"Completed","enrollment":" Enrollment 149","initiation":"Initiation: 10/01/2014","start_date":" 10/01/2014","primary_txt":" Primary completion: 03/01/2020","primary_completion_date":" 03/01/2020","study_txt":" Completion: 04/01/2020","study_completion_date":" 04/01/2020","last_update_posted":"2020-07-14"},{"id":"68437971-9714-4d65-858d-5223d19a23aa","acronym":"","url":"https://clinicaltrials.gov/study/NCT01462175","created_at":"2021-01-18T06:04:54.371Z","updated_at":"2024-07-02T16:37:27.822Z","phase":"Phase 1","brief_title":"A First-In-Human Study of RO5503781 in Participants With Advanced Malignancies Except Leukemia","source_id_and_acronym":"NCT01462175","lead_sponsor":"Hoffmann-La Roche","biomarkers":" TP53 • MDM2 • GDF15 • CDKN1A","pipe":" | ","alterations":" TP53 mutation","tags":["TP53 • MDM2 • GDF15 • CDKN1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e idasanutlin (RG7388)"],"overall_status":"Completed","enrollment":" Enrollment 99","initiation":"Initiation: 11/01/2011","start_date":" 11/01/2011","primary_txt":" Primary completion: 07/01/2014","primary_completion_date":" 07/01/2014","study_txt":" Completion: 07/01/2014","study_completion_date":" 07/01/2014","last_update_posted":"2016-11-02"}]